BR9815781A - Alquila, arila ou heteroarilamidas substituìdas em 3 por n-hidróxi-2-(alquila, arila, ou heteroarila sulfanila, sulfinila ou sulfonila) como inibidores da metaloproteinase de matriz - Google Patents
Alquila, arila ou heteroarilamidas substituìdas em 3 por n-hidróxi-2-(alquila, arila, ou heteroarila sulfanila, sulfinila ou sulfonila) como inibidores da metaloproteinase de matrizInfo
- Publication number
- BR9815781A BR9815781A BR9815781-7A BR9815781A BR9815781A BR 9815781 A BR9815781 A BR 9815781A BR 9815781 A BR9815781 A BR 9815781A BR 9815781 A BR9815781 A BR 9815781A
- Authority
- BR
- Brazil
- Prior art keywords
- aryl
- alkyl
- heteroaryl
- tnf
- tace
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/14—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
Abstract
Patente de Invenção: <B>"ALQUILA, ARILA OU HETEROARILAMIDAS SUBSTITUìDAS EM 3 POR N-HIDRóXI-2-(ALQUILA, ARILA, OU HETEROARILA SULFANILA, SULFINILA OU SULFONILA) COMO INIBIDORES DA METALOPROTEINASE DE MATRIZ"<D>. As metaloproteinases de matriz (MMPs) são um grupo de enzimas que têm estado implicadas na destruição patológica do tecido conjuntivo e das membranas basais. Estas endopeptidases contendo zinco consistem em diversos subgrupos de enzimas, incluindo as colagenases, as estromelisinas e as gelatinases. A enzima de conversão de TNF-<244> (TACE), uma citocina pró-inflamatória, catalisa a formação de TNF-<244> a partir da proteína precursora de TNF-<244> ligada a membrana. é esperado que os inibidores, com pequenas moléculas, de MMPs e TACE, portanto, tenham o potencial para tratar uma variedade de estados de doenças. A presente invenção proporciona inibidores com baixo peso molecular, que não são peptídeos, de metaloproteinases de matriz (MMPs) e de enzima de conversão de TNF-<244> (TACE), para o tratamento de artrite, metástase do tumor, ulceração do tecido, cicatrização anormal do ferimento, doença periodontal, doença óssea, diabetes (resistência à insulina) e infecção por HIV, tendo a fórmula (I), na qual R² e R³ formam um anel heterocíclico e A é S, S(O), ou S(O)~ 2~ e R¹ e R^ 4^ são definidos aqui.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2637298A | 1998-02-19 | 1998-02-19 | |
PCT/US1998/017633 WO1999042436A1 (en) | 1998-02-19 | 1998-08-26 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9815781A true BR9815781A (pt) | 2000-11-07 |
Family
ID=21831431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9815781-7A BR9815781A (pt) | 1998-02-19 | 1998-08-26 | Alquila, arila ou heteroarilamidas substituìdas em 3 por n-hidróxi-2-(alquila, arila, ou heteroarila sulfanila, sulfinila ou sulfonila) como inibidores da metaloproteinase de matriz |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1054858A1 (pt) |
JP (1) | JP2002503717A (pt) |
KR (1) | KR20010041089A (pt) |
CN (1) | CN1213021C (pt) |
AU (1) | AU757719B2 (pt) |
BG (1) | BG104782A (pt) |
BR (1) | BR9815781A (pt) |
CA (1) | CA2320469A1 (pt) |
EA (1) | EA003283B1 (pt) |
EE (1) | EE200000471A (pt) |
GE (1) | GEP20022797B (pt) |
HR (1) | HRP20000543A2 (pt) |
HU (1) | HUP0101837A3 (pt) |
ID (1) | ID25639A (pt) |
IL (1) | IL137566A0 (pt) |
NO (1) | NO20004093L (pt) |
NZ (1) | NZ506184A (pt) |
PL (1) | PL342548A1 (pt) |
SK (1) | SK12332000A3 (pt) |
TR (1) | TR200002423T2 (pt) |
WO (1) | WO1999042436A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010039287A1 (en) * | 1997-11-14 | 2001-11-08 | Thomas E Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
RU2250105C2 (ru) | 1997-11-14 | 2005-04-20 | Дж.Д.Сёрл ЛЛС | Ароматическая сульфонгидроксамовая кислота в качестве ингибитора металлопротеаз |
US6750228B1 (en) | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
CN1178915C (zh) * | 1999-01-27 | 2004-12-08 | 惠氏控股有限公司 | 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途 |
AR035312A1 (es) * | 1999-01-27 | 2004-05-12 | Wyeth Corp | Compuestos de acido hidroxamico que contienen alquinilo como inhibidores de metaloproteinasa de matriz/tace, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamento |
US6800646B1 (en) | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
GEP20043238B (en) | 1999-02-08 | 2004-05-25 | Searle & Co | Sulfamato Hydroxamic Acid Metalloprotease Inhibitor, its Use in Preparation of Pharmaceutical Composition for Treatment of Conditions Associated with Pathological Matrix Metalloprotease Activity |
JP2003520852A (ja) * | 2000-01-27 | 2003-07-08 | アメリカン・サイアナミド・カンパニー | α−スルホニルヒドロキサム酸誘導体を製造する方法 |
AR028537A1 (es) * | 2000-04-14 | 2003-05-14 | Abbott Lab | Hidrazidas y alcoxiamidas inhibidoras de la angiogénesis |
US20020002152A1 (en) | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
US6683093B2 (en) | 2000-05-12 | 2004-01-27 | Pharmacia Corporation | Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
EA200301116A1 (ru) | 2001-05-11 | 2004-06-24 | Фармация Корпорейшн | Гидроксаматы ароматических сульфонов и их применение в качестве ингибиторов протеаз |
JP2005537228A (ja) | 2002-04-25 | 2005-12-08 | ファルマシア・コーポレーション | ピペリジニル−及びピペラジニル−スルホニルメチルヒドロキサム酸並びにプロテアーゼ阻害剤としてのその使用 |
BR0312036A (pt) * | 2002-06-25 | 2005-04-05 | Pharmacia Corp | ácido arilsulfonilhidroxâmico e derivados de amida bem como composição farmacêutica contendo os mesmos e uso dos mesmos |
US7098241B2 (en) | 2002-12-16 | 2006-08-29 | Hoffmann-La Roche Inc. | Thiophene hydroxamic acid derivatives |
CA2585766A1 (en) * | 2004-11-01 | 2006-05-11 | Nuada, Llc | Compounds and methods of use thereof |
FR2917427B1 (fr) * | 2007-06-18 | 2009-08-21 | Galderma Res & Dev | Inhibiteurs de tace dans le traitement de l'acne |
FR2947268B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
AU2013292076B2 (en) * | 2012-07-18 | 2017-02-23 | Proyecto De Biomedicina Cima, S.L. | New antifibrinolytic compounds |
WO2016032120A1 (ko) * | 2014-08-27 | 2016-03-03 | 씨제이헬스케어 주식회사 | 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도 |
KR101641023B1 (ko) * | 2014-08-27 | 2016-07-20 | 씨제이헬스케어 주식회사 | 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도 |
CN107188837B (zh) * | 2017-06-06 | 2019-05-28 | 温州大学 | 一种α-酰基高烯丙基硫醚类化合物的合成方法 |
EP3860608A1 (en) | 2018-10-04 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8827305D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
KR970700652A (ko) * | 1994-01-22 | 1997-02-12 | 포올 리틀우드 | 금속단백질 분해효소 억제제 |
CA2193691A1 (en) * | 1994-06-22 | 1995-12-28 | Andrew Miller | Metalloproteinase inhibitors |
DK0970046T3 (da) * | 1997-02-27 | 2004-04-13 | Wyeth Corp | N-Hydroxy-2-(alkyl-, aryl- eller heteroarylsulfanyl, -sulfinyl eller -sulfonyl)-3-substituerede alkyl- eller heteroaryl-amider som matrixmetalloproteinaseinhibitorer |
JPH11199512A (ja) * | 1997-10-24 | 1999-07-27 | Pfizer Prod Inc | 変形性関節症および他のmmp媒介疾患の治療のためのmmp−13選択的阻害剤の使用 |
RU2250105C2 (ru) * | 1997-11-14 | 2005-04-20 | Дж.Д.Сёрл ЛЛС | Ароматическая сульфонгидроксамовая кислота в качестве ингибитора металлопротеаз |
-
1998
- 1998-08-26 HU HU0101837A patent/HUP0101837A3/hu unknown
- 1998-08-26 SK SK1233-2000A patent/SK12332000A3/sk unknown
- 1998-08-26 CN CNB988139669A patent/CN1213021C/zh not_active Expired - Fee Related
- 1998-08-26 BR BR9815781-7A patent/BR9815781A/pt not_active Application Discontinuation
- 1998-08-26 WO PCT/US1998/017633 patent/WO1999042436A1/en not_active Application Discontinuation
- 1998-08-26 CA CA002320469A patent/CA2320469A1/en not_active Abandoned
- 1998-08-26 TR TR2000/02423T patent/TR200002423T2/xx unknown
- 1998-08-26 NZ NZ506184A patent/NZ506184A/en unknown
- 1998-08-26 EA EA200000849A patent/EA003283B1/ru not_active IP Right Cessation
- 1998-08-26 AU AU91201/98A patent/AU757719B2/en not_active Ceased
- 1998-08-26 PL PL98342548A patent/PL342548A1/xx unknown
- 1998-08-26 KR KR1020007009128A patent/KR20010041089A/ko not_active Application Discontinuation
- 1998-08-26 GE GEAP19985554A patent/GEP20022797B/en unknown
- 1998-08-26 JP JP2000532389A patent/JP2002503717A/ja active Pending
- 1998-08-26 ID IDW20001549A patent/ID25639A/id unknown
- 1998-08-26 IL IL13756698A patent/IL137566A0/xx unknown
- 1998-08-26 EE EEP200000471A patent/EE200000471A/xx unknown
- 1998-08-26 EP EP98943392A patent/EP1054858A1/en not_active Withdrawn
-
2000
- 2000-08-16 NO NO20004093A patent/NO20004093L/no unknown
- 2000-08-18 HR HR20000543A patent/HRP20000543A2/hr not_active Application Discontinuation
- 2000-09-19 BG BG104782A patent/BG104782A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
JP2002503717A (ja) | 2002-02-05 |
IL137566A0 (en) | 2001-07-24 |
TR200002423T2 (tr) | 2001-01-22 |
HUP0101837A3 (en) | 2001-11-28 |
WO1999042436A1 (en) | 1999-08-26 |
HUP0101837A2 (hu) | 2001-10-28 |
NO20004093D0 (no) | 2000-08-16 |
EE200000471A (et) | 2002-02-15 |
PL342548A1 (en) | 2001-06-18 |
GEP20022797B (en) | 2002-09-25 |
ID25639A (id) | 2000-10-19 |
HRP20000543A2 (en) | 2001-08-31 |
CN1213021C (zh) | 2005-08-03 |
EA200000849A1 (ru) | 2001-04-23 |
KR20010041089A (ko) | 2001-05-15 |
NZ506184A (en) | 2003-05-30 |
CA2320469A1 (en) | 1999-08-26 |
NO20004093L (no) | 2000-10-03 |
EP1054858A1 (en) | 2000-11-29 |
AU9120198A (en) | 1999-09-06 |
AU757719B2 (en) | 2003-03-06 |
BG104782A (bg) | 2001-08-31 |
SK12332000A3 (sk) | 2001-02-12 |
EA003283B1 (ru) | 2003-04-24 |
CN1291183A (zh) | 2001-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9815781A (pt) | Alquila, arila ou heteroarilamidas substituìdas em 3 por n-hidróxi-2-(alquila, arila, ou heteroarila sulfanila, sulfinila ou sulfonila) como inibidores da metaloproteinase de matriz | |
BR9807803A (pt) | N-hidróxi-2-(alquil, aril ou heteroaril sulfanil, sulfinil ou sulfonil) -alquila, arila ou heteroarilamidas 3-substituìdas como inibidores da metaloproteinase matricial | |
BR9910122A (pt) | Compostos amidina | |
AR009990A1 (es) | Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienen | |
BR9907997A (pt) | Promotor especìfico de pólen | |
ES2107648T3 (es) | Acidos hidroxamicos substituidos con arilsulfonamido. | |
BR0210358A (pt) | Inibidores da protease de hiv, composições contendo os mesmos, seus usos farmacêuticos e materiais para sua sìntese | |
NO921609L (no) | Sulfonamider og deres medisinske anvendelse | |
TNSN02012A1 (fr) | Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant | |
ATE197044T1 (de) | Sulfonamide, ihre herstellung und verwendung als heilmittel und zwischenprodukte | |
AR022906A1 (es) | Amidas de aminoacidos modificadas, medicamentos que contienen estos compuestos y procedimiento para su preparacion | |
BR0200341A (pt) | Bifenilsulfonamidas proveitosas como inibidores de metaloproteases da matriz | |
AR008676A1 (es) | Acidos beta-sulfonamido hidrosamicos como inhibidores de la metaloproteinasa de matriz y tace, uso de los mismos en la preparacion de unmedicamento y una composicion farmaceutica que los contienen | |
NO921187L (no) | Nye azadecalinamider og thioamider som inhibitorer av kolesterolbiosyntese | |
BR0011291A (pt) | Derivados de ácido hidroxâmico como inibidores de metaloprotease de matriz | |
BR0007759A (pt) | Composto, processo para preparar o mesmo,composição farmacêutica, e, métodos para tratarcondições de doença mediadas pelametaloproteinase de matriz em um mamìfero emnecessidade deste, e para tratar um paciente quesofre de uma condição selecionada do grupo queconsiste de osteoartrite, artrite reumatóide,perda de cartilagem degenerativa edesenvolvimento de tumor | |
NO20060718L (no) | Substituerte tiofoner og deres anvendelse | |
PT1071704E (pt) | Novos inibidores e reguladores negativos das metaloproteinases da matriz | |
BR9809577A (pt) | Processo e intermediários para a prepração da (1,2,3,4-tetraidro-isoquinolin-6-il)-amida do ácido 4'-trifluormetil-bifenil-2-carboxìlico | |
BRPI0211635B8 (pt) | composto ciclo-hexil-sulfona, uso do mesmo, e, composição farmacêutica | |
ATE356114T1 (de) | Inhibitoren von metalloproteinasen | |
DE3881691D1 (de) | Polydeoxyribonukleotide, pharmazeutische zusammensetzungen, verwendung und herstellung von polydeoxyribonukleotiden. | |
ATE420068T1 (de) | Reverse hydroxamsäurederivate | |
BR9902943A (pt) | Uma sìntese eficaz de compostos furanossulfonamida úteis para a sìntese de novos inibidores de il-1. | |
BR0100601A (pt) | Compostos de ácido 6-amino- ou 6-hidrazino-sulfonil-3-quinolinil-fosfÈnico, processo para sua preparação e composições farmacêuticas que os contêm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |